NasdaqCM - Delayed Quote • USD
Cellectar Biosciences, Inc. (CLRB)
At close: June 7 at 4:00 PM EDT
After hours: June 7 at 6:09 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 5 | 2 | 4 | 5 |
| Avg. Estimate | -1 | -0.72 | -3.91 | -2.83 |
| Low Estimate | -1.43 | -0.75 | -4.72 | -5.15 |
| High Estimate | -0.69 | -0.7 | -2.61 | -1.32 |
| Year Ago EPS | -0.9 | -1 | -4.3 | -3.91 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| No. of Analysts | 3 | 1 | 3 | 3 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 12/31/2021 | 3/31/2022 | 6/30/2022 | 9/30/2022 |
|---|---|---|---|---|
| EPS Est. | -1.02 | -1 | -1.03 | -1.21 |
| EPS Actual | -0.9 | -1 | -1.22 | -1.28 |
| Difference | 0.12 | 0 | -0.19 | -0.07 |
| Surprise % | 11.80% | 0.00% | -18.40% | -5.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Current Estimate | -1 | -0.72 | -3.91 | -2.83 |
| 7 Days Ago | -1.23 | -0.6 | -4.46 | -2.21 |
| 30 Days Ago | -1.23 | -0.6 | -4.46 | -2.69 |
| 60 Days Ago | -1.13 | 0 | -4.25 | -4.14 |
| 90 Days Ago | -1.13 | 0 | -4.25 | -4.14 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2022) | Next Qtr. (Mar 2023) | Current Year (2022) | Next Year (2023) |
|---|---|---|---|---|
| Up Last 7 Days | 3 | -- | 3 | 2 |
| Up Last 30 Days | 3 | -- | 3 | 3 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| CURRENCY IN USD | CLRB | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -11.10% | -- | -- | 9.10% |
| Next Qtr. | 28.00% | -- | -- | 11.50% |
| Current Year | 9.10% | -- | -- | 5.70% |
| Next Year | 27.60% | -- | -- | 12.60% |
| Next 5 Years (per annum) | -- | -- | -- | 11.34% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Roth MKM: Buy to Buy | 3/28/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 3/28/2024 |
| Reiterates | Roth MKM: Buy to Buy | 3/4/2024 |
| Maintains | HC Wainwright & Co.: Buy | 11/4/2022 |
Related Tickers
ASMB Assembly Biosciences, Inc.
14.28
-9.33%
ALGS Aligos Therapeutics, Inc.
0.5401
-6.56%
SPRO Spero Therapeutics, Inc.
1.4050
-3.10%
GRTX Galera Therapeutics, Inc.
0.1090
-3.11%
CYTK Cytokinetics, Incorporated
52.79
+0.98%
MDNAF Medicenna Therapeutics Corp.
1.7500
+1.16%
MREO Mereo BioPharma Group plc
3.4200
-0.58%
NXTC NextCure, Inc.
1.3900
+13.01%
CTMX CytomX Therapeutics, Inc.
1.6400
-1.80%
NERV Minerva Neurosciences, Inc.
3.2200
-4.17%